K-vescent Efffervescent
Loading...K-vescent Efffervescent Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
The administration of potassium salts can produce hyperkalemia and cardiac arrest in patients with impaired mechanisms for potassium excretion. These reactions most commonly occur in patients receiving potassium intravenously, but may also occur in patients receiving oral potassium. Potentially fatal hyperkalemia can develop quickly and be asymptomatic. Patients using potassium salts with chronic renal disease, or any other condition which impairs the excretion of potassium, require especially careful monitoring of serum potassium concentration and appropriate adjustment of dosage.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in digitalis intoxication and in patients with hypokalemic familial periodic paralysis.
For prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions; patients receiving digitalis and
diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states.
The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a
normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated.
History
There is currently no drug history available for this drug.
Other Information
An oral potassium supplement. Each effervescent tablet in solution provides 25 mEq of potassium as supplied by 2.4g potassium bicarbonate with 1.4g Citric Acid, FD and C Yellow #6 Dye, FD and C Yellow #6 Lake, Natural Orange Flavor, Polyethylene Glycol, Saccharin, Sodium Benzoate, and Sorbitol.
Sources
K-vescent Efffervescent Manufacturers
-
Major Pharmaceuticals
![K-vescent Efffervescent (Potassium Bicarbonate) Tablet, Effervescent [Major Pharmaceuticals]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
K-vescent Efffervescent | Major Pharmaceuticals
Adults - One effervescent tablet (25 mEq potassium) completely dissolved in three to four ounces or more of cold water and taken two to four times daily, or as directed by physician. It is suggested this potassium solution be taken with meals and sipped slowly over a five to ten minute period. Do not open foil pouch until time of use.
-
Cardinal Health
K-vescent Efffervescent | Cardinal Health
2.1 Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)The recommended starting dose of atorvastatin calcium tablets is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin calcium tablets is 10 to 80 mg once daily. Atorvastatin calcium tablets can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin calcium tablets should be individualized according to patient characteristics such as goal of therapy and response (see current NCEP Guidelines). After initiation and/or upon titration of atorvastatin calcium tablets, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.
2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 to 17 years of age)The recommended starting dose of atorvastatin calcium tablets is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy [see current NCEP Pediatric Panel Guidelines, Clinical Pharmacology (12), and Indications and Usage (1.2)]. Adjustments should be made at intervals of 4 weeks or more.
2.3 Homozygous Familial HypercholesterolemiaThe dosage of atorvastatin calcium tablets in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin calcium tablets should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.
2.4 Concomitant Lipid-Lowering TherapyAtorvastatin calcium tablets may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see Warnings and Precautions, Skeletal Muscle (5.1), Drug Interactions (7)].
2.5 Dosage in Patients With Renal ImpairmentRenal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary [see Warnings and Precautions, Skeletal Muscle (5.1), Clinical Pharmacology, Pharmacokinetics (12.3)].
2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease InhibitorsIn patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), therapy with atorvastatin should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary employed. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with atorvastatin should be limited to 20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin is employed. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, therapy with atorvastatin should be limited to 40 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin is employed [see Warnings and Precautions, Skeletal Muscle (5.1), Drug Interactions (7)].
![K-vescent Efffervescent (Potassium Bicarbonate) Tablet, Effervescent [Cardinal Health]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed0d5c17-0481-4d6b-8051-8d6e47f49ce5&name=image-05.jpg)
Login To Your Free Account